Free shipping on all orders over $ 500

LX2343

Cat. No. M10070

All AbMole products are for research use only, cannot be used for human consumption.

LX2343 Structure
Synonym:

LX-2343

Size Price Availability Quantity
5mg USD 105 In stock
10mg USD 165 In stock
50mg USD 540 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LX2343 is a BACE1 enzyme inhibitor with IC50 value of 11.43±0.36 μM, and it is a neuroprotective agent. LX2343 (5-20 μM) dose-dependently decreased Aβ accumulation in HEK293-APPsw and CHO-APP cells, and promotes Aβ clearance in SH-SY5Y cells and primary astrocytes. LX2343 ameliorates cognitive dysfunction in APP/PS1 transgenic mice via both Aβ production inhibition and clearance promotion, which highlights the potential of LX2343 in the treatment of AD. LX2343 ameliorates the cognitive dysfunction in the AD model rats by suppressing OS-induced neuronal apoptosis and tauopathy, thus highlighting the potential of LX2343 for the treatment of AD. In the probe trial assay, the LX2343-administered transgenic mice cross over the hidden location of the platform more frequently compared with the vehicle-administered transgenic mice.

Chemical Information
Molecular Weight 474.91
Formula C22H19ClN2O6S
CAS Number 333745-53-2
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Guanglong Sun, et al. Eur J Med Chem. Design, synthesis and biological evaluation of LX2343 derivatives as neuroprotective agents for the treatment of Alzheimer's disease

[2] Xiao-Dan Guo, et al. Acta Pharmacol Sin. LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy

[3] Xiao-Dan Guo, et al. Acta Pharmacol Sin. Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance

Related BACE Products
LY2886721

LY2886721 is an effective, selective, orally active inhibitor of beta-site amyloid precursor protein lyase 1 (BACE1) with an IC50 of 20.3 nM against recombinant human BACE1. LY2886721 showed higher selectivity for BACE1 than cathepsin D, pepsin and renin, but lacked selectivity for BACE2 (IC50 was 10.2 nM). LY2886721 crosses the blood-brain barrier and can be used to study Alzheimer's disease.

AZD3839

AZD3839 is a potent and selective inhibitor of human BACE1 with Ki of 26.1 nM.

Lanabecestat

Lanabecestat (AZD3293, LY3314814) is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor.

Eslicarbazepine Acetate

Eslicarbazepine acetate is an antiepileptic drug.

Verubecestat (MK-8931)

Verubecestat (MK-8931) is an orally active, high-affinity (beta-secretase 1) BACE1 and BACE2 inhibitor, with Ki values of 2.2 nM and 0.38 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: LX2343, LX-2343 supplier, BACE, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.